Search

Neisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen

Eletriptan

Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.

Bismuth subsalicylate

Each molecule of bismuth subsalicylate contains 58% bismuth and 42% salicylate by weight. … [A230728, A230773] Bismuth subsalicylate was first approved by the FDA in 1939 and is now mainly used to relieve nausea, diarrhea, and gastrointestinal discomfort.

Seladelpar

[L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

Nitrofurantoin

[L6856,L6859,L6862] Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein.

Batroxobin

Batroxobin is inactivated by alpha2-macroglobulin, but not anti-thrombin compounds. Batroxobin will also bind fibrinogen in a manner different than thrombin and with a higher affinity. … Currently use is experimental but trials have been conducted which support certain clinical applications. Recombinant Batroxobin in relatively affordable and could be accessed by mass production.

Vimseltinib

[L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate

Tasonermin

It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent removal of the tumor and in palliative care for irresectable soft tissue sarcoma

Amoxicillin

[A190648] Amoxicillin has similar activity to [penicillin] and [ampicillin], but leads to higher serum concentrations than ampicillin.

Anileridine

Some of their side effects are also caused by actions in the CNS.